Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Haematol. 2013 Feb;90(2):89-98. doi: 10.1111/ejh.12043.

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.

Author information

1
Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA. sverstov@mdanderson.org

Abstract

Apart from indolent systemic mastocytosis (SM), which is associated with a favorable prognosis, other subtypes of SM (SM with associated clonal hematologic non-mast cell lineage disease, aggressive SM, and mast cell leukemia - collectively referred to in this review as advanced SM) can be debilitating. The complexity of SM makes both the diagnosis and design of response criteria challenging for clinical studies. The tyrosine kinase KIT has been shown to play a crucial role in the pathogenesis of SM and has been a focal point in the development of targeted therapy. Mutations within various domains of the KIT receptor that lead to constitutive activation have been identified in patients, and those involving the activation loop of the KIT receptor are the mutations most frequently detected in patients with mastocytosis. Aberrant activation of the KIT receptor results in increased production of mast cells in extracutaneous organs that may lead to organ failure or early death. This review discusses the diagnosis and management of patients with advanced SM, including the relevance of KIT in this disease, potential therapies targeting this kinase, and criteria for measuring responses to these therapies.

PMID:
23181448
PMCID:
PMC3761194
DOI:
10.1111/ejh.12043
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center